I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting                 multiple sclerosis predominantly by reducing gray matter atrophy

Zivadinov, Robert; Locatelli, Laura; Cookfair, Diane L.; Srinivasaraghavan, Bhooma; Bertolotto, Antonio; Ukmar, Maja; Bratina, Alessio; Maggiore, Cosimo; Bosco, Antonio; Grop, Attilio; Catalan, Mauro; Zorzon, Marino

doi:10.1177/1352458506070446

Cited by 72 publications

(88 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[23][24][25][26]43 Despite these known effects of treatment with intramuscular interferon ␤-1a, both patients with SDP and those with stable MS exhibited loss of brain tissue during the course of this study. The extent of atrophy in untreated patients with MS is likely to be greater than that observed in the treated patients in this study, though it is not known whether the differential pattern of WM and GM atrophy would be as evident.…”

Section: Discussionmentioning

confidence: 99%

“…These findings are in agreement with those in previous studies that have suggested differential patterns of GM and WM atrophy during 2 years for patients with MS versus healthy controls 6 and that the rate of GM, but not WM, atrophy increased with advancing disease stage and was correlated with disability. 4,5,12,24,25 Fundamentally cross-sectional approaches like SIENAX are still widely used to measure GM and WM changes, 25 leading to potentially less accurate results and more analysis failures. Direct measures of cortical, GM, and WM volume changes with advantages similar to those of SIENA have been lacking.…”

Section: Discussionmentioning

confidence: 99%

“…[23][24][25] Most important, intramuscular interferon ␤-1a has been shown to significantly slow the progression of brain atrophy in patients with RRMS, primarily through a reduction in GM atrophy. 25,26 The aim of the current study was to monitor the temporal dynamics of SDGM and cortical atrophy in patients with early RRMS who participated in an intramuscular interferon ␤-1a study during 5 years and to determine any association with disability progression.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

Zivadinov

Bergsland

Doležal³

et al. 2013

AJNR Am J Neuroradiol

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

Zivadinov

Bergsland

Doležal³

et al. 2013

AJNR Am J Neuroradiol

Self Cite

View full text Add to dashboard Cite

show abstract

“…132,144 Future studies will undoubtedly explore the regional topography of such treatment effects as the relative effect on GM versus WM. 145 Atrophy measures are being incorporated into studies that explore the efficacy and safety of novel MS therapies. New data have emerged from natalizumab, 146 autologous hematopoietic stem cell transplantation, 147,148 and testosterone.…”

Section: Brain Atrophymentioning

confidence: 99%

MRI in Multiple Sclerosis: What’s Inside the Toolbox?

et al. 2007

View full text Add to dashboard Cite

Summary: Magnetic resonance imaging (MRI) has played a central role in the diagnosis and management of multiple sclerosis (MS). In addition, MRI metrics have become key supportive outcome measures to explore drug efficacy in clinical trials. Conventional MRI measures have contributed to the understanding of MS pathophysiology at the macroscopic level yet have failed to provide a complete picture of underlying MS pathology. They also show relatively weak relationships to clinical status such as predictive strength for clinical progression. Advanced quantitative MRI measures such as magnetization transfer, spectroscopy, diffusion imaging, and relaxometry techniques are somewhat more specific and sensitive for underlying pathology. These measures are particularly useful in revealing diffuse damage in cerebral white and gray matter and therefore may help resolve the dissociation between clinical and conventional MRI findings. In this article, we provide an overview of the array of tools available with brain and spinal cord MRI technology as it is applied to MS. We review the most recent data regarding the role of conventional and advanced MRI techniques in the assessment of MS. We focus on the most relevant pathologic and clinical correlation studies relevant to these measures.

show abstract

“…One study suggests a benefit of interferon beta-1a (Avonex) in slowing the rate of gray matter atrophy, detectable at 2 and 3 years after initiating treatment [80]. Another recent study found that gray matter loss was detected in patients treated with interferon-β but not in untreated or Copaxone-treated patients assessed over a 2-year period using a voxel-based morphometry approach [81].…”

Section: Fig 1 Serial Cerebral Magnetic Resonance (Mr) Images Demonmentioning

confidence: 99%

Neuroimaging in Multiple Sclerosis: Neurotherapeutic Implications

Sicotte

2011

Neurotherapeutics

View full text Add to dashboard Cite

Summary: Imaging techniques, in particular magnetic resonance imaging (MRI), play an important role in the diagnosis and management of multiple sclerosis (MS) and related demyelinating diseases. Findings on MRI studies of the brain and spinal cord are critical for MS diagnosis, are used to monitor treatment response and may aid in predicting disease progression in individual patients. In addition, results of imaging studies serve as essential biomarkers in clinical trials of putative MS therapies and have led to important insights into disease pathophysiology. Although they are useful tools and provide in vivo measures of disease-related activity, there are some important limitations of MRI findings in MS, including the non-specific nature of detectable white matter changes, the poor correlation with clinical disability, the limited sensitivity and ability of standard measures of gadolinium enhancing lesions and T2 lesions to predict future clinical course, and the lack of validated biomarkers of long term outcomes. Advancements that hold promise for the future include new techniques that are sensitive to diffuse changes, the increased use of higher field scanners, measures that capture disease related changes in gray matter, and the use of combined structural and functional imaging approaches to assess the complex and evolving disease process that occurs during the course of MS.

show abstract

I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy

Abstract: Over a three-year period, treatment with IFN beta-1a significantly slowed the progression of whole-brain and GM atrophy, and of T1-hypointense LV accumulation, when compared with the control group.

Cited by 72 publications

References 58 publications

Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years

MRI in Multiple Sclerosis: What’s Inside the Toolbox?

Neuroimaging in Multiple Sclerosis: Neurotherapeutic Implications

Contact Info

Product

Resources

About